CClinicalTrials.gg
RecruitingNCT02584270PGSRTUpdated May 8, 2026

Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue

An interventional study of Palatal Augmentation Prosthesis (PAP) and Articulation Therapy in Tongue Neoplasms, Tongue Cancer and Oral Cancer, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by University of Michigan · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis (PAP) as a therapeutic modality post-surgery. This is a robust scientific randomized prospective clinical trial.

Positive outcomes from this study have the potential to dramatically alter the most common issues of oral cancer therapy, namely speech and swallowing functions. Patients will have been diagnosed with a cancer lesion of the tongue requiring surgery and removal of part of the tongue. Smaller cancers of the tongue are sized as T1 or T2. For patients with smaller lesions, a PAP, which can aid in speaking and swallowing, is not routinely provided.

Read the detailed description

This study will randomize patients into two arms; one for oral cancer patients that receive a small device, similar to a denture, called a PAP. The other arm will be patients who serve as a control and will not receive a PAP.

The PAP requires patients to have a dental mold created. A dentist customizes the PAP to specifically fit the individual's mouth.

The study will investigate whether the PAP improves speech following tongue cancer as measured by three different scales. Both groups will see a speech language therapist for additional measures of speech evaluation.

02

Conditions studied

  • Tongue Neoplasms
  • Tongue Cancer
  • Oral Cancer

Keywords

  • palatal drop prosthesis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with a new diagnosis of a T1/T2 tongue cancer

Exclusion criteria

Exclusion Criteria:

  • Patients with recurrent disease
  • Patients with a history of prior head and neck radiation therapy
  • Patients who lack adequate maxillary dentition to support a palatal augmentation prosthesis
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Prosthesis + Articulation Therapy

    This arm will receive a PAP (palatal augmentation prosthesis) with standard articulation therapy. This is the study arm

    Device: Palatal Augmentation Prosthesis (PAP) · Other: Articulation Therapy

  • Other
    No Prosthesis; Articulation Therapy Only

    This arm will not receive a PAP (palatal augmentation prosthesis), but will receive standard articulation therapy. This is the control arm.

    Other: Articulation Therapy

Interventions

  • DevicePalatal Augmentation Prosthesis (PAP)

    The palatal augmentation prosthesis, or PAP can improve speech and swallowing functions through reshaping the palatal contours. This may improve the contact between the tongue and hard palate as a person speaks or eats. It is meant to be created after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and articulation therapy are necessary for this therapy to be effective.

  • OtherArticulation Therapy

    Subjects will receive the standard of care speech and articulation therapy in either arm.

    Also known as: Speech Therapy

05

What researchers measure

Primary outcomes

  1. Word intelligibility

    The Assessment of Intelligibility of Dysarthric speech (AIDS) test is a validated assessment of word and sentence intelligibility as well as speech efficiency. The AIDS score will be measured at baseline before surgery for tongue cancer, then after surgery at the timepoints of one month, three months, six months and one year. Six months is the primary time point measurement. Measurements will also be obtained at these other time points, which will possibly be used for other outcome analysis which are neither primary nor secondary. The unit being measured will be a percent score of words correctly transcribed by two blinded untrained listeners of the subjects' audio recordings of separate un-related words.

    Time frame: 6 months

Secondary outcomes

  1. Sentence intelligibility

    The Assessment of intelligibility of dysarthric speech (AIDS) test is a validated assessment of word and sentence intelligibility as well as speech efficiency and will be measured at baseline before surgery for tongue cancer, then post-operatively at one month, three months, six months and one year. Six months is the primary time point measurement, although measurements will also be obtained at these other time points, which will possibly be used for other outcome analysis which are neither primary nor secondary. The unit being measured will be a percent score of words correctly transcribed by two blinded untrained listeners of the subjects' audio recordings of words in sentences.

    Time frame: 6 months

  2. Articulation at the word level of phonemes (consonant sounds)

    The Goldman Fristoe 2 test of Articulation sounds in words subtest (GFTA2) is a standardized, validated and reliable tool that systematically assesses articulation of phonemes (consonant sounds). It offers normative data from ages 2 through 21. This will be measured at baseline pre-treatment of tongue cancer, then post-operatively at one month, three months, six months and one year. Six months is the primary time point measurement, although measurements will also be obtained at these other time points, which will possibly be used for other outcome analysis which are neither primary nor secondary. The unit being measured is the raw score generated from the test.

    Time frame: 6 months

  3. Patient satisfaction with speech

    The Speech Handicap Index (SHI) is designed to evaluate an individual's speech function and corresponding psycho-social factors. This will be measured at baseline pre-treatment of tongue cancer, then post-operatively at one month, three months, six months and one year. Six months is the primary time point measurement, although measurements will also be obtained at these other time points, which will possibly be used for other outcome analysis which are neither primary nor secondary. The unit being measured is the mean score of the survey.

    Time frame: 6 months

06

Study locations

1 of 1 sites recruiting
  • University of Michigan Department of Oral and Maxillofacial Surgery and Hospital Dentistry
    Ann Arbor, Michigan 48109, United States
    Recruiting
07

Registry details

Key details

Study ID
NCT02584270
Lead sponsor
University of Michigan
Responsible party
Stephanie M. Munz (Clinical Assistant Professor, University of Michigan) — Principal investigator
First posted
Oct 22, 2015
Start date
Jan 2, 2018
Primary completion
Jan 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
May 8, 2026

Study contacts

Stephanie M Munz, DDS
Contact
smmunz@med.umich.edu
734 936-8289
Mary Burton
Contact
mjburt@med.umich.edu
Stephanie M Munz, DDS
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion